Granted Patent
B2
US 12,329,899 · App. 15/701,257 · Granted Jun 17, 2025
Dry powder inhaler and methods of use
Assignee:
ASPEYA US INC.
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Methods for reducing the risk of a thromboembolic event, and a related drug delivery system are provided. In some embodiments, a dose of acetylsalicylic acid can be provided in powder form to a patient using a dry powder inhaler. The dose can be effective to reduce a risk of a thromboembolic event in a patient. A dry powder inhaler used for the method can have a mouthpiece, a reservoir for receiving the dose of acetylsalicylic acid, and an actuation member for making available the dose of acetylsalicylic acid for inhalation by a patient through the mouthpiece.
Claims (29)
1. A method of reducing a risk of a thromboembolic event in a patient in an emergency, the method comprising:
administering through oral inhalation to the patient a dose of a dry powder consisting essentially of acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof, and, optionally, at least one carrier, particles of the dry powder having a median geometric diameter in a range of from 1 μm to 5 μm,
wherein the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof in the dose is in a range of from 1 mg to less than 80 mg.
2. The method of claim 1 , wherein the dose has less than 75 mg of the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof.
3. The method of claim 1 , wherein the administering is a preliminary treatment in response to a symptom of the thromboembolic event.
4. The method of claim 1 , wherein the median geometric diameter is in a range of from 1.7 μm to 2.7 μm.
5. The method of claim 1 , wherein the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof in the dose administered is bioequivalent to an oral dose in a range of from 81 mg to 325 mg of acetylsalicylic acid.
6. The method of claim 1 , which treats a pulmonary embolism.
7. The method of claim 1 , wherein the acetylsalicylic acid is present in the dry powder.
8. The method of claim 1 , wherein the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof in the dose is in a range of from 2 mg to 60 mg.
9. The method of claim 1 , wherein the particles are spheroidal and have a sponge-like morphology.
10. A drug delivery system for reducing a risk of a thromboembolic event in an emergency, the system comprising:
a dose of a dry powder consisting essentially of acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof, and, optionally, at least one carrier, particles of the dry powder having a median geometric diameter in a range of from 1 μm to 5 μm; and
a dry powder inhaler suitable for oral inhalation,
wherein the dose has the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof in a range of from 1 mg to less than 80 mg, wherein the dry powder inhaler comprises a mouthpiece and a reservoir suitable for receiving the dose.
11. The system of claim 10 , wherein the dose has less than 75 mg of the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof.
12. The system of claim 10 , wherein the median geometric diameter is in a range of from 1.7 μm to 2.7 μm.
13. The system of claim 10 , wherein the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof in the dose is in a range of from 2 mg to 60 mg.
14. The system of claim 10 , wherein the particles are spheroidal and have a sponge-like morphology.
15. A method of reducing a risk of a thromboembolic event in a patient in an emergency, the method comprising:
administering through oral inhalation to the patient a dose of a dry powder consisting of acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof, and, optionally, at least one carrier, particles of the dry powder having a median geometric diameter in a range of from 1 μm to 5 μm,
wherein the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof in the dose is in a range of from 1 mg to less than 80 mg.
16. The method of claim 15 , wherein the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof in the dose is in a range of from 2 mg to 60 mg.
17. The method of claim 15 , wherein the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof is present in the dry powder in a range of from 2 mg to 30 mg.
18. The method of claim 15 , wherein the particles are spheroidal and have a sponge-like morphology.
19. The method of claim 15 , wherein the dry powder consists of particles of the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof and the at least one carrier.
20. The method of claim 15 , wherein the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof is administered in only a single dose.
21. The method of claim 15 , wherein the dry powder consists of particles consisting of the acetylsalicylic acid and one carrier.
22. The method of claim 15 , wherein the acetylsalicylic acid and/or at least one pharmaceutically acceptable salt thereof is not administered in a single dose.
Assignments (3)
CONFIRMATION OF ASSIGNMENT
Recorded Apr 24, 2023
From: OTITOPIC INC.
To: VECTURA INC.
Reel/Frame 063448/0621 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Nov 15, 2018
From: YADIDI, KAMBIZ
To: OTITOPIC INC.
Reel/Frame 047519/0493 →
Continuity (4)
Provisional Application
61740407
· Dec 20, 2012
References Cited (317)
US 3906950A
· Cozza
· 1975
[cited by applicant]
US 4353365A
· Hallworth et al.
· 1982
[cited by applicant]
US 4885287A
· Hussain
· 1989
[cited by applicant]
US 4995385A
· Valentini et al.
· 1991
[cited by applicant]
US 5256538A
· Aiken et al.
· 1993
[cited by applicant]
US 5327883A
· Williams et al.
· 1994
[cited by applicant]
US 5366967A
· Bianco
· 1994
[cited by examiner]
US 5506203A
· Backstrom et al.
· 1996
[cited by applicant]
US 5518998A
· Backstrom et al.
· 1996
[cited by applicant]
US 5639441A
· Sievers et al.
· 1997
[cited by applicant]
US 5673686A
· Villax et al.
· 1997
[cited by applicant]
US 5750559A
· Bianco
· 1998
[cited by applicant]
US 5855913A
· Hanes et al.
· 1999
[cited by applicant]
US 5874064A
· Edwards et al.
· 1999
[cited by applicant]
US 5875776A
· Vaghefi
· 1999
[cited by examiner]
US 6051256A
· Platz et al.
· 2000
[cited by applicant]
US 6051566A
· Bianco
· 2000
[cited by applicant]
US 6098620A
· Lloyd et al.
· 2000
[cited by applicant]
US 6136295A
· Edwards et al.
· 2000
[cited by applicant]
US 6136346A
· Eljamal et al.
· 2000
[cited by applicant]
US 6187344B1
· Eljamal et al.
· 2001
[cited by applicant]
US 6254854B1
· Edwards et al.
· 2001
[cited by applicant]
US 6257233B1
· Burr
· 2001
[cited by examiner]
US 6284282B1
· Maa et al.
· 2001
[cited by applicant]
US 6309623B1
· Weers et al.
· 2001
[cited by applicant]
US 6358530B1
· Eljamal et al.
· 2002
[cited by applicant]
US 6408846B1
· Ohki et al.
· 2002
[cited by applicant]
US 6423344B1
· Platz et al.
· 2002
[cited by applicant]
US 6455028B1
· Wulffhart et al.
· 2002
[cited by applicant]
US 6503480B1
· Edwards et al.
· 2003
[cited by applicant]
US 6516950B1
· Robertson
· 2003
[cited by examiner]
US 6561186B2
· Casper et al.
· 2003
[cited by applicant]
US 6565885B1
· Tarara et al.
· 2003
[cited by applicant]
US 6569406B2
· Stevenson et al.
· 2003
[cited by applicant]
US 6592904B2
· Platz et al.
· 2003
[cited by applicant]
US 6630169B1
· Bot et al.
· 2003
[cited by applicant]
US 6638495B2
· Weers et al.
· 2003
[cited by applicant]
US 6652837B1
· Edwards et al.
· 2003
[cited by applicant]
US 6705313B2
· Niccolai
· 2004
[cited by applicant]
US 6732732B2
· Edwards et al.
· 2004
[cited by applicant]
US 6737042B2
· Rabinowitz et al.
· 2004
[cited by applicant]
US 6766799B2
· Edwards et al.
· 2004
[cited by applicant]
US 6848197B2
· Chen et al.
· 2005
[cited by applicant]
US 6880555B1
· Brunnberg et al.
· 2005
[cited by applicant]
US 6881398B2
· Myrman et al.
· 2005
[cited by applicant]
US 6884794B2
· Staniforth et al.
· 2005
[cited by applicant]
US 6893657B2
· Roser et al.
· 2005
[cited by applicant]
US 6979437B2
· Bartus et al.
· 2005
[cited by applicant]
US 6994842B2
· Lee et al.
· 2006
[cited by applicant]
US 6998137B2
· Shih et al.
· 2006
[cited by applicant]
US 7025059B2
· Pera
· 2006
[cited by applicant]
US 7089934B2
· Staniforth et al.
· 2006
[cited by applicant]
US 7146978B2
· Edwards et al.
· 2006
[cited by applicant]
US 7189750B2
· Assaf et al.
· 2007
[cited by applicant]
US 7201929B1
· Finkelstein
· 2007
[cited by applicant]
US 7205343B2
· Dellamary et al.
· 2007
[cited by applicant]
US 7267813B2
· Watanabe et al.
· 2007
[cited by applicant]
US 7278425B2
· Edwards et al.
· 2007
[cited by applicant]
US 7284553B2
· Hochrainer
· 2007
[cited by applicant]
US 7306787B2
· Tarara et al.
· 2007
[cited by applicant]
US 7405207B2
· Leonard et al.
· 2008
[cited by applicant]
US 7431916B2
· Nilsson et al.
· 2008
[cited by applicant]
US 7435720B2
· Quay et al.
· 2008
[cited by applicant]
US 7516741B2
· Glusker et al.
· 2009
[cited by applicant]
US 7521068B2
· Bosch et al.
· 2009
[cited by applicant]
US 7534914B2
· Koike et al.
· 2009
[cited by applicant]
US 7541022B2
· Staniforth et al.
· 2009
[cited by applicant]
US 7556035B2
· Young et al.
· 2009
[cited by applicant]
US 7556798B2
· Edwards et al.
· 2009
[cited by applicant]
US 7559325B2
· Dunkley et al.
· 2009
[cited by applicant]
US 7628978B2
· Weers et al.
· 2009
[cited by applicant]
US 7651770B2
· Berkland et al.
· 2010
[cited by applicant]
US 7669596B2
· Alston
· 2010
[cited by applicant]
US 7682614B2
· Strober et al.
· 2010
[cited by applicant]
US 7744906B2
· Coates
· 2010
[cited by applicant]
US 7790145B2
· Weers et al.
· 2010
[cited by applicant]
US 7806117B2
· Tsutsui
· 2010
[cited by applicant]
US 7878193B2
· Kladders et al.
· 2011
[cited by applicant]
US 7919119B2
· Straub et al.
· 2011
[cited by applicant]
US 7954491B2
· Hrkach
· 2011
[cited by applicant]
US 8069851B2
· Dunkley et al.
· 2011
[cited by applicant]
US 8075919B2
· Brown et al.
· 2011
[cited by applicant]
US 8114438B2
· Pipkin et al.
· 2012
[cited by applicant]
US 8168223B1
· Tarara et al.
· 2012
[cited by applicant]
US 8173168B2
· Platz et al.
· 2012
[cited by applicant]
US 8201555B2
· Chawla
· 2012
[cited by applicant]
US 8236786B2
· Finch et al.
· 2012
[cited by applicant]
US 8246934B2
· Weers et al.
· 2012
[cited by applicant]
US 8530463B2
· Cartt et al.
· 2013
[cited by applicant]
US 8561609B2
· Donovan et al.
· 2013
[cited by applicant]
US 8623419B2
· Malakhov et al.
· 2014
[cited by applicant]
US 8771744B2
· Ruecroft et al.
· 2014
[cited by applicant]
US 8790648B2
· Tocker et al.
· 2014
[cited by applicant]
US 8795634B2
· Illum et al.
· 2014
[cited by applicant]
US 8940683B2
· Levitt
· 2015
[cited by applicant]
US 8985102B2
· Hodson et al.
· 2015
[cited by applicant]
US 8997799B2
· Hodson et al.
· 2015
[cited by applicant]
US 9051302B2
· Winssinger et al.
· 2015
[cited by applicant]
US 9061352B2
· Lipp et al.
· 2015
[cited by applicant]
US 9085632B2
· Coates et al.
· 2015
[cited by applicant]
US 9101539B2
· Nagata et al.
· 2015
[cited by applicant]
US 9125999B2
· Rolfs et al.
· 2015
[cited by applicant]
US 9138407B2
· Caponetti et al.
· 2015
[cited by applicant]
US 20020025917A1
· Pappalardo
· 2002
[cited by applicant]
US 20020033174A1
· Lecourt
· 2002
[cited by examiner]
US 20020128179A1
· Tacon
· 2002
[cited by examiner]
US 20020158150A1
· Matsugi
· 2002
[cited by examiner]
US 20030000518A1
· Rabinowitz
· 2003
[cited by examiner]
US 20030176421A1
· Watson et al.
· 2003
[cited by applicant]
US 20030186843A1
· Staniforth et al.
· 2003
[cited by applicant]
US 20030232019A1
· Basu et al.
· 2003
[cited by applicant]
US 20040049022A1
· Nyce et al.
· 2004
[cited by applicant]
US 20040092470A1
· Leonard et al.
· 2004
[cited by applicant]
US 20040105821A1
· Bernstein et al.
· 2004
[cited by applicant]
US 20040206350A1
· Alston et al.
· 2004
[cited by applicant]
US 20040235802A1
· Gimona
· 2004
[cited by examiner]
US 20050004079A1
· Benjamin et al.
· 2005
[cited by applicant]
US 20050084528A1
· Saeed et al.
· 2005
[cited by applicant]
US 20050148555A1
· Gupta et al.
· 2005
[cited by applicant]
US 20050180926A1
· Lecourt et al.
· 2005
[cited by applicant]
US 20050249697A1
· Uhrich et al.
· 2005
[cited by applicant]
US 20060002995A1
· Harwigsson
· 2006
[cited by applicant]
US 20060030550A1
· Lithgow et al.
· 2006
[cited by applicant]
US 20060257987A1
· Gonzalez Valcarcel et al.
· 2006
[cited by applicant]
US 20060293217A1
· Barker et al.
· 2006
[cited by applicant]
US 20070072939A1
· Kupper
· 2007
[cited by applicant]
US 20070116761A1
· Desai et al.
· 2007
[cited by applicant]
US 20070123571A1
· Raj et al.
· 2007
[cited by applicant]
US 20070160661A1
· Finkelstein
· 2007
[cited by examiner]
US 20070178166A1
· Bernstein et al.
· 2007
[cited by applicant]
US 20070232575A1
· Baulieu et al.
· 2007
[cited by applicant]
US 20080066741A1
· LeMahieu et al.
· 2008
[cited by applicant]
US 20080127972A1
· Morton
· 2008
[cited by examiner]
US 20090011030A1
· Jouhikainen et al.
· 2009
[cited by applicant]
US 20090110679A1
· Li et al.
· 2009
[cited by applicant]
US 20090136561A1
· Von Rechenberg et al.
· 2009
[cited by applicant]
US 20090220435A1
· Quay et al.
· 2009
[cited by applicant]
US 20090312380A1
· Becker
· 2009
[cited by applicant]
US 20100168710A1
· Braithwaite
· 2010
[cited by applicant]
US 20100234442A1
· Duarte-Vazquez et al.
· 2010
[cited by applicant]
US 20100242960A1
· Zangerle
· 2010
[cited by applicant]
US 20100258118A1
· Morton
· 2010
[cited by applicant]
US 20100316724A1
· Whitfield et al.
· 2010
[cited by applicant]
US 20100319694A1
· Cook et al.
· 2010
[cited by applicant]
US 20110112134A1
· Hutchinson et al.
· 2011
[cited by applicant]
US 20110142914A1
· Persaud et al.
· 2011
[cited by applicant]
US 20110189106A1
· Danzig et al.
· 2011
[cited by applicant]
US 20110263610A1
· Wan et al.
· 2011
[cited by applicant]
US 20110277752A1
· Cheu et al.
· 2011
[cited by applicant]
US 20120046251A1
· Schaefer et al.
· 2012
[cited by applicant]
US 20120064126A1
· Sung et al.
· 2012
[cited by applicant]
US 20120125325A1
· Bannister et al.
· 2012
[cited by applicant]
US 20120276193A1
· Graversen et al.
· 2012
[cited by applicant]
US 20120308566A1
· Martin et al.
· 2012
[cited by applicant]
US 20130004969A1
· Peschon et al.
· 2013
[cited by applicant]
US 20130028942A1
· Surber et al.
· 2013
[cited by applicant]
US 20130316001A1
· Popov et al.
· 2013
[cited by applicant]
US 20140079784A1
· Burnier et al.
· 2014
[cited by applicant]
US 20140234330A1
· Budelsky et al.
· 2014
[cited by applicant]
US 20140239525A1
· McConville et al.
· 2014
[cited by applicant]
US 20140242174A1
· Walker
· 2014
[cited by applicant]
US 20140322238A1
· Budelsky et al.
· 2014
[cited by applicant]
US 20150005230A1
· Eliasof
· 2015
[cited by applicant]
US 20150050713A1
· Malakhov et al.
· 2015
[cited by applicant]
US 20150059746A1
· Green
· 2015
[cited by applicant]
US 20150093338A1
· Farber
· 2015
[cited by applicant]
US 20150136130A1
· Dehaan et al.
· 2015
[cited by applicant]
US 20150224129A1
· Trottein et al.
· 2015
[cited by applicant]
US 20150284381A1
· Andresen et al.
· 2015
[cited by applicant]
CN 1388762
· 2003
[cited by applicant]
CN 1491109
· 2004
[cited by applicant]
CN 102058886
· 2011
[cited by applicant]
EP 0499143A2
· 1992
[cited by examiner]
EP 1177805
· 2002
[cited by applicant]
EP 1238680
· 2002
[cited by applicant]
EP 1350511
· 2003
[cited by applicant]
EP 1814521
· 2007
[cited by applicant]
EP 1350511B1
· 2008
[cited by applicant]
GB 2434754
· 2007
[cited by applicant]
JP H4500070
· 1992
[cited by applicant]
JP 2002255814
· 2002
[cited by applicant]
JP 2003525081
· 2003
[cited by applicant]
JP 2004509141
· 2004
[cited by applicant]
JP 2009537199
· 2009
[cited by applicant]
WO WO9300951
· 1993
[cited by applicant]
WO WO9511666
· 1995
[cited by applicant]
WO 9737708A1
· 1997
[cited by applicant]
WO 2000027359
· 2000
[cited by applicant]
WO WO2002024158
· 2002
[cited by applicant]
WO 03047598
· 2003
[cited by applicant]
WO 03047628
· 2003
[cited by applicant]
WO 2005040163
· 2005
[cited by applicant]
WO 2005041886
· 2005
[cited by applicant]
WO 2006017354
· 2006
[cited by applicant]
WO 2007072503
· 2007
[cited by applicant]
WO 2009089822
· 2009
[cited by applicant]
WO 2012061902
· 2012
[cited by applicant]
WO 2012107364
· 2012
[cited by applicant]
WO 2012107765
· 2012
[cited by applicant]
WO 2013004999
· 2013
[cited by applicant]
WO 2014131851
· 2014
[cited by applicant]
WO 2014155103
· 2014
[cited by applicant]
WO 2015002703
· 2015
[cited by applicant]
WO 2015011244
· 2015
[cited by applicant]
WO 2015054574
· 2015
[cited by applicant]
WO 2015127315
· 2015
[cited by applicant]
WO 2015148415
· 2015
[cited by applicant]
WO 2015153838
· 2015
[cited by applicant]
WO 2015155544
· 2015
[cited by applicant]
Keller, Developments and trends in pulmonary drug delivery, Chemistry today, 1998.
[cited by examiner]
Miser, Appropriate use for primary prevention of cardiovascular disease, Editorials: controversies in family medicine 2011.
[cited by examiner]
Kallmann et al., Effects of low doses of aspirin, 10 mg and 30 mg daily, on bleeding time, thromboxane production and 6-keto PGF1 alpha excretion in healthy subjects, Thromb Res, 1987.
[cited by examiner]
WebMD, Heart attack signs, symptoms and emergency treatment 2011.
[cited by examiner]
Eikelboom et al., Antiplatelet Drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines, Chest, vol. 141, Issue 2, Supplement, …
[cited by examiner]
Diener et al., European Stroke Prevention Study 2. Dipyridamole and acetylsalicylic acid in the secondary prevention of stroke, Journal of the Neurological Sciences, vol. 143, Issues 1-2, 1996, pp. 1-13, ISSN 0022-510X,…
[cited by examiner]
Algra, et al., “Aspirin at Any Dose Above 30 mg Offers Only Modest Protection After Cerebral Ischaemia,” J of Neurology, Neurosurgery & Psychiatry, 1996, 60:197-199.
[cited by applicant]
Asprin Dosage-Drugs, www.druigs.com, Dec. 2011.
[cited by applicant]
“Aspirin”, Martindale: The Complete Drug Reference, 33rd ed., 2002 Pharmaceutical press, pp. 14-18.
[cited by applicant]
ATT Collaboration, “Aspirin in the Primary and Secondary Prevention of Vascular Disease: Collaborative Meta-Analysis of Individual Participant Data from Randomised Trials,” The Lancet, 2009, 373:1849-1860.
[cited by applicant]
Awa, et al., “Prediction of time-dependent interaction of aspirin with ibuprofen using a pharmacokinetic/pharmacodynamics model,” Journal of Clinical Pharmacy and Therapeutics, 2012, vol. 37, pp. 469-474.
[cited by applicant]
Boysen, et al., “Danish Very-low-dose Aspirin After Carotid Endarterectomy Trial,” Stroke, 1988, 19:1211-1215.
[cited by applicant]
Chew, et al., “The Role of Particle Properties in Pharmaceutical Powder Inhalation Formulations,” Journal of Aerosol Medicine, 2002, vol. 15, No. 3, pp. 325-330.
[cited by applicant]
Christen, et al., “Low-dose Aspirin and Risk of Cataract and Subtypes in a Randomized Trial of U.S. Physicians” Ophthalmic Epidemiology, 1998, vol. 5, No. 3, pp. 133-142.
[cited by applicant]
European Search Report dated Jul. 18, 2016 corresponding to European Application No. 13864747.4; 6 pages.
[cited by applicant]
Fehri, et al., “Bioavailability of Acetylsalicylic Acid Administered Orally or Rectally in the Rabbit,” J. Pharma Belg, 1989, vol. 44, No. 1, pp. 5-10.
[cited by applicant]
Geller, et al., “Development of an Inhaled Dry-Powder Formulation of Tobramycin Using PlumoSphere Technology,” J Aerosol Med Pulm Drug Deliv, Aug. 2011, 24(4), pp. 175-182.
[cited by applicant]
Hadinoto et al., “Drug Release Study of Large Hollow Nanoparticulate Aggregates Carrier Particles for Pulmonary Delivery,” International Journal of Pharmaceutics 341 (2007) 195-206.
[cited by applicant]
Hadinoto, et al., “Dry powder aerosol delivery of large hollow nanoparticulate aggregates as prospective carriers of nanoparticulate drugs: Effects of phospholipids,” International Journal of Pharmaceuticals, Oct. 2006,…
[cited by applicant]
Hovens et al., Aspirin in the prevention and treatment of venous thromboembolism, Journal of Thrombosis and Haemostasis, 2006; 4: 1470-5.
[cited by applicant]
Hovione TwinCaps Dry Powder Inhaler, <http://www.hovione.com/twincaps/twincaps.asp>, visited Aug. 2013.
[cited by applicant]
Hovione—Particle Design Technologies, <http://www.hovione.com/pd/particledesigntechnologies.asp>, visited Aug. 2013.
[cited by applicant]
“Internal Analgesic: Antipyretic, and Antirheumatic Drug Products for Over-the-Counter Human Use: Final Rule for Professional Labeling of Aspirin, Buffered Aspirin, and Aspirin in Combination with Antacid Drug Products,…
[cited by applicant]
Iwamoto, “Gastrointestinal and Hepatic First-Pass Metabolism of Aspirin in Rats,” J Pharm Pharmacol. Mar. 1982; 34(3), pp. 176-180.
[cited by applicant]
Jaffe, et al., “Recovery of Endothelial Cell Prostacyclin Production after Inhibition by Low Doses of Aspirin,” The American Society for Clinical Investigation, Inc., Mar. 1979, vol. 63, pp. 532-535.
[cited by applicant]
Kim, et al., “Airway Responsiveness to Inhaled Aspirin is Influenced by Airway Hyperresponsiveness in Asthmatic Patients,” Korean J Intern Med, Sep. 2010; 25(3): 309-316.
[cited by applicant]
Kupczyk, et al. “Lipoxin A4 Generation Is Decreased in Aspirin-Sensitive Patients in Lysine-Aspirin Nasal Challenge in Vivo Model”, Allergy (Oxford, United Kingdom) (2009), 64(12), 1746-1752.
[cited by applicant]
Kurth, et al., “Inhibition of Clinical Benefits of Aspirin on First Myocardial Infarction by Nonsteroidal Antiinflammatory Drugs,” Circulation, 2003, 108:1191-1195.
[cited by applicant]
Miser, Appropriate Aspirin Use for Primary Prevention of Cardiovascular Disease, Editorials: Controversies in Family Medicine, 2011.
[cited by applicant]
Phillips et al., “Inhaled Lysine-Aspirin as a Bronchoprovocation Procedure in Aspirin-Sensitive Asthma: its Repeatability, Absence of a Late-Phase Reaction, and the Role of Histamine,” J Allergy Clin Immunol, Aug. 1989;…
[cited by applicant]
Press release by Activaero GmbH, Dec. 19, 2006, <http://www.pharmaloco.com/news.sub.—detail/Activaero+and+Group+of+Re- saerchers+Receive+Grant+for+Develop/14009/index.html>.
[cited by applicant]
“Physicians' Health Study I,” <http://phs.bwh.harvard.edu/phs1.htm>, Mar. 2009.
[cited by applicant]
Rocca, et al., “Variability in the Responsiveness to Low-Dose Aspirin: Pharmacological and Disease-Related Mechanisms,” Thrombosis, 2012, 11 pages.
[cited by applicant]
Roth, et al., “Aspirin, Platelets, and Thrombosis: Theory and Practice,” Blood, Feb. 15, 1994, vol. 83, No. 4, pp. 885-898.
[cited by applicant]
Sestini et al., “Different Effects of Inhaled Aspirin-like Drugs on Allergen-Induced Early and Late Asthmatic Responses,” Am J Respir Grit Care Med, Apr. 1, 1999 vol. 159 No. 4 1228-1233.
[cited by applicant]
Sestini, et al., “Protective Effect of Inhaled Lysine Acetylsalicylate on Allergen-Induced Early and Late Asthmatic Reactions,” J Allergy Clin Immunol, 1997 vol. 100, pp. 71-77.
[cited by applicant]
Soleti et al., “Aspirin Inhalation Treatment for COPD Patients: Preliminary Studies on PK and Inflammatory Biomarkers,” Thematic Poster Session, P825, Drug delivery and pharmacokinetics I, Sep. 25, 2011, p. 138s.
[cited by applicant]
Sung, et al., “Nanoparticles for Drug Delivery to the Lungs,” Trends in Biotechnology, 2007, vol. 25, No. 12.
[cited by applicant]
The Dutch TIA Trial Study Group, “A Comparison of Two Doses of Aspirin (30 mg vs. 283 mg a day) in Patients After a Transient Ischemic Attack or Minor Ischemic Stroke,” The New England Journal of Medicine, 1991, vol. 32…
[cited by applicant]
WebMD Heart Attack; 2011.
[cited by applicant]
Canadian Intellectual Property Office, “First Office Action”, for Canadian Application No. 2,895,398, dated Nov. 8, 2016, 4 pgs.
[cited by applicant]
Canadian Intellectual Property Office, “Second Office Action”, for Canadian Application No. 2,895,398, dated Sep. 27, 2017, 4 pgs.
[cited by applicant]
European Patent Office, “Official Action (Article 94(3)) EPC”, for EP13864747.4, dated Oct. 5, 2017, 4 pgs.
[cited by applicant]
IP Australia, “First Examination Report”, for AU 2013205497, dated Aug. 19, 2014, 4 pgs.
[cited by applicant]
IP Australia, “Second Examination Report”, for AU 2013205497, dated Nov. 9, 2015, 3 pgs.
[cited by applicant]
IP Australia, “First Examination Report”, for AU 2016213728, dated Oct. 12, 2017, 4 pgs.
[cited by applicant]
Japanese Patent Office, “First Office Action” for JP 2015-549353 with English translation, dated Aug. 1, 2016 6 pgs.
[cited by applicant]
Japanese Patent Office, “Second Office Action” for JP 2015-549353, dated Apr. 19, 2017, 5 pgs.
[cited by applicant]
State Intellectual Property Office of China PRC, “First Office Action” for CN 201380073320.3 (English translation), dated Aug. 11, 2016, 6 pgs.
[cited by applicant]
State Intellectual Property Office of China PRC, “Second Office Action” for CN 201380073320.3 with partial English translation, dated May 3, 2017, 6 pgs.
[cited by applicant]
USPTO, “International Search Report and Written Opinion” for international application No. PCT/US2013/032597, dated Jun. 11, 2013, 7 pgs.
[cited by applicant]
Office Action dated Nov. 3, 2016, in co-pending U.S. Appl. No. 13/791,734.
[cited by applicant]
Stroke Prevention in Atrial Fibrillation Investigators (“Risk factors for thromboembolism during aspirin therapy in patients with atrial fibrillation: the stroke prevention in atrial fibrillation study”, J Stroke Cerebr…
[cited by applicant]
Aspirin the mighty drug (year 2007).
[cited by applicant]
Barnett et al., Aspirin Dose in Stroke Prevention, Stroke, 1996; 27:588.
[cited by applicant]
Office Actions dated Dec. 8, 2021, in co-pending U.S. Appl. No. 16/370,932.
[cited by applicant]
Office Actions dated Apr. 27, 2023, in co-pending U.S. Appl. No. 16/370,932.
[cited by applicant]
Office Action with a mailing date of Jun. 30, 2016 on the corresponding Japanese Patent Application No. 2015-549353 (with Machine English translation).
[cited by applicant]
Office Action with a mailing date of Mar. 22, 2018 on the corresponding Japanese Patent Application No. 2015-549353 (with Machine English translation).
[cited by applicant]
Notice of Allowance with a mailing date of Sep. 5, 2018 on the corresponding Japanese Patent Application No. 2015- 549353 (with Machine English translation).
[cited by applicant]
Office Action with a mailing date of May 3, 2017 on the corresponding Chinese Patent Application No. 201380073320.3 (with Machine English translation).
[cited by applicant]
Extended European Search Report with a mailing date of Sep. 29, 2023, issued in corresponding Application No. EP 23 16 4415.4 (reference 24 cited therein).
[cited by applicant]
Anne Van Hecken, PhD et al.; “Comparative Inhibitory Activity of Rofecoxib, Meloxicam, Diclofenac, Ibuprofen, and Naproxen on COX-2 versus COX-1 in Healthy Volunteers”, The Journal of Clinical Pharmacology, Lippincott C…
[cited by applicant]
Patrono, C. et al., “Low-Dose Aspirin for the Prevention of Atherothrombosis”, New England Journal of Medicine, 2005, pp. 2373-2383.
[cited by applicant]
Swarbrick, J., “Encyclopedia of Pharmaceutical Technology”, New York, USA: Informa Healthcare, 2007, Ed. Third—pp. 1279-1286 and cover pages.
[cited by applicant]
Dai, Y et al., “Clinical Use of Aspirin in Treatment and Prevention of Cardiovascular Disease”, Thrombosis, vol. 2012, Article ID 245037, 2021, pp. 1-7.
[cited by applicant]
British National Formulary “British National Formulary 61” BMJ Group and Pharmaceutical Press, 2011 - pp. 149-152 and cover pages.
[cited by applicant]
Patentee's letter dated Mar. 9, 2021, and enclosure “Exhibit C” filed during examination, 8 pages.
[cited by applicant]
Aulton M.E., “Pharmaceutics: The Science of Dosage Form Design”, Churchill Livingstone, 2022, Ed. Second, 18 pages.
[cited by applicant]
Proof of online publication of D5 on Nov. 24. 2011, available from: https://www.ncbi.nlm.nih.gov/pms/articles/PMC3236445.
[cited by applicant]